Male hypogonadism : an update on diagnosis and treatment.
暂无分享,去创建一个
[1] R. Casaburi,et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. , 2005, The Journal of clinical endocrinology and metabolism.
[2] W. Bremner,et al. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. , 2005, The Journal of clinical endocrinology and metabolism.
[3] A. Matsumoto,et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. , 2005, The Journal of clinical endocrinology and metabolism.
[4] Duane D. Miller,et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. , 2004, Endocrinology.
[5] A. Araujo,et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. , 2004, The Journal of clinical endocrinology and metabolism.
[6] U. Jonas,et al. Review article Testosterone therapy in the ageing male: what about the prostate? , 2004, Andrologia.
[7] T. Gasser,et al. Is there a clinical relevance of partial androgen deficiency of the aging male? , 2004, The Journal of urology.
[8] A. Dobs,et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. , 2004, The Journal of clinical endocrinology and metabolism.
[9] R. Jones,et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life , 2004, Heart.
[10] Ali Iranmanesh,et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. , 2004, The Journal of clinical endocrinology and metabolism.
[11] M. Korbonits,et al. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. , 2004, The Journal of clinical endocrinology and metabolism.
[12] C. Christiansen,et al. The aging male: testosterone deficiency and testosterone replacement. An up-date. , 2004, Atherosclerosis.
[13] David Handelsman,et al. Testosterone release rate and duration of action of testosterone pellet implants , 2004, Clinical Endocrinology.
[14] A. Hoffman,et al. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men , 2004, BJU international.
[15] A. Dobs,et al. Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men , 2004, Current medical research and opinion.
[16] Christina Wang,et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. , 2004, The Journal of clinical endocrinology and metabolism.
[17] N. Watts,et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. , 2004, The Journal of clinical endocrinology and metabolism.
[18] A. Morgentaler,et al. Risks of testosterone-replacement therapy and recommendations for monitoring. , 2004, The New England journal of medicine.
[19] P. Stattin,et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study , 2004, International journal of cancer.
[20] Ruth Etzioni,et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[21] B. Anawalt,et al. Male hypogonadism in the primary care clinic. , 2003, Primary care.
[22] S. Bhasin. Testosterone supplementation for aging-associated sarcopenia. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.
[23] P. Delmas,et al. Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. , 2003, The Journal of clinical endocrinology and metabolism.
[24] W. Schill,et al. A new oral testosterone undecanoate formulation , 2003, World Journal of Urology.
[25] B. Lunenfeld. Androgen therapy in the aging male , 2003, World Journal of Urology.
[26] G. Scriba,et al. Oral testosterone-triglyceride conjugate in rabbits: single-dose pharmacokinetics and comparison with oral testosterone undecanoate. , 2003, Journal of andrology.
[27] H. Perry,et al. Andropause: an old concept in new clothing. , 2003, Clinics in geriatric medicine.
[28] Michael M Lieber,et al. The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.
[29] Matthew T. Haren,et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. , 2003, The journals of gerontology. Series A, Biological sciences and medical sciences.
[30] C. Reiners,et al. Osteoporosis in Male Hypogonadism: Responses to Androgen Substitution Differ among Men with Primary and Secondary Hypogonadism , 2003, Hormone Research in Paediatrics.
[31] T. Smith,et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. , 2003, The Journal of clinical endocrinology and metabolism.
[32] Richard A. Anderson,et al. Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. , 2003, The Journal of clinical endocrinology and metabolism.
[33] W. Fraser,et al. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle‐aged men compared with those in young men , 2003, Clinical endocrinology.
[34] S. Bhasin,et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. , 2003, Journal of andrology.
[35] T. Smith,et al. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim™, compared to AndroGel® , 2003, Biopharmaceutics & drug disposition.
[36] A. von Eckardstein,et al. Androgens and coronary artery disease. , 2003, Endocrine reviews.
[37] Duane D. Miller,et al. Pharmacodynamics of Selective Androgen Receptor Modulators , 2003, Journal of Pharmacology and Experimental Therapeutics.
[38] J. Chung,et al. Oral testosterone undecanoate (Andriol®) supplement therapy improves the quality of life for men with testosterone deficiency , 2003, The aging male : the official journal of the International Society for the Study of the Aging Male.
[39] J. Kaufman. The effect of androgen supplementation therapy on the prostate , 2003, The aging male : the official journal of the International Society for the Study of the Aging Male.
[40] A. Matsumoto,et al. Testosterone Supplementation Therapy for Older Men: Potential Benefits and Risks , 2003, Journal of the American Geriatrics Society.
[41] T. McNicholas,et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function , 2003, BJU international.
[42] J. Patrie,et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. , 2002, The Journal of clinical endocrinology and metabolism.
[43] A. Morales,et al. Androgen deficiency in the aging male: when, who, and how to investigate and treat. , 2002, The Urologic clinics of North America.
[44] S. Petak,et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. , 2002, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[45] E. Nieschlag,et al. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation , 2002, Clinical endocrinology.
[46] H. Perry,et al. Evaluation of assays available to measure free testosterone. , 2002, Metabolism: clinical and experimental.
[47] D. Kadmon,et al. The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial , 2002 .
[48] R. Swerdloff,et al. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? , 2002, The Journal of clinical endocrinology and metabolism.
[49] O. Itkonen,et al. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. , 2002, The Journal of clinical endocrinology and metabolism.
[50] David Handelsman,et al. A randomised controlled clinical trial of antibiotic impregnation of testosterone pellet implants to reduce extrusion rate. , 2002, European journal of endocrinology.
[51] R. Wolfe,et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. , 2002, American journal of physiology. Endocrinology and metabolism.
[52] A. Matsumoto. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.
[53] A. Matsumoto,et al. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. , 2002, Journal of andrology.
[54] A. Vermeulen,et al. Diagnosis of hypogonadism in the aging male , 2002, The aging male : the official journal of the International Society for the Study of the Aging Male.
[55] R. Casaburi,et al. Testosterone dose-response relationships in healthy young men. , 2001, American journal of physiology. Endocrinology and metabolism.
[56] David Handelsman,et al. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants , 2001, Clinical endocrinology.
[57] David Handelsman,et al. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. , 2001, The Journal of clinical endocrinology and metabolism.
[58] D. Siscovick,et al. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. , 2001, The American journal of medicine.
[59] A. Iranmanesh,et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men , 2001, Clinical endocrinology.
[60] Keith C. Norris,et al. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. , 2001, The Journal of clinical endocrinology and metabolism.
[61] A. Dobs,et al. Hypogonadism and androgen replacement therapy in elderly men. , 2001, The American journal of medicine.
[62] A. Kenny,et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.
[63] E. Metter,et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. , 2001, The Journal of clinical endocrinology and metabolism.
[64] A. Iranmanesh,et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. , 2000, The Journal of clinical endocrinology and metabolism.
[65] J. Mckinlay,et al. Construction and field validation of a self‐administered screener for testosterone deficiency (hypogonadism) in ageing men , 2000, Clinical endocrinology.
[66] R. Steeds,et al. Chronic Stable Angina : A Randomized , Double-Blind , Placebo-Controlled Study Low-Dose Transdermal Testosterone Therapy Improves Angina Threshold in Men With , 2000 .
[67] H. Perry,et al. Validation of a screening questionnaire for androgen deficiency in aging males. , 2000, Metabolism: clinical and experimental.
[68] A. Kenny,et al. Determinants of bone density in healthy older men with low testosterone levels. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.
[69] J. Berlin,et al. Effects of testosterone replacement in hypogonadal men. , 2000, The Journal of clinical endocrinology and metabolism.
[70] A. Iranmanesh,et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. , 2000, The Journal of clinical endocrinology and metabolism.
[71] E. Nieschlag,et al. Hormone substitution in male hypogonadism , 2000, Molecular and Cellular Endocrinology.
[72] R. Swerdloff,et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. , 2000, The Journal of clinical endocrinology and metabolism.
[73] C. Mantzoros,et al. Hormonal predictors of prostate cancer: a meta-analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] E. Nieschlag,et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men , 1999, Clinical endocrinology.
[75] J. Suvisaari,et al. Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. , 1999, Contraception.
[76] D. Baird,et al. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. , 1999, The Journal of clinical endocrinology and metabolism.
[77] S. Arver,et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. , 1999, The Journal of clinical endocrinology and metabolism.
[78] David Handelsman,et al. Extrusion of testosterone pellets: a randomized controlled clinical study , 1999, Clinical endocrinology.
[79] A. Vermeulen,et al. A critical evaluation of simple methods for the estimation of free testosterone in serum. , 1999, The Journal of clinical endocrinology and metabolism.
[80] J. Suvisaari,et al. Gonadotrophin and testosterone suppression by 7alpha-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men. , 1999, Human reproduction.
[81] J. Berlin,et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. , 1999, The Journal of clinical endocrinology and metabolism.
[82] M. Horan,et al. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. , 1999, International journal of andrology.
[83] T. Key,et al. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies , 1999, British Journal of Cancer.
[84] J. Berlin,et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. , 1999, The Journal of clinical endocrinology and metabolism.
[85] E. Nieschlag,et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. , 1999, European journal of endocrinology.
[86] M. Schubert,et al. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. , 1999, Metabolism: clinical and experimental.
[87] E. Nieschlag,et al. Long‐term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years , 1999, Clinical endocrinology.
[88] M. Armitage,et al. Experience with transdermal testosterone replacement therapy for hypogonadal men , 1999, Clinical endocrinology.
[89] D. Cummings,et al. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. , 1998, The Journal of clinical endocrinology and metabolism.
[90] W. Bremner,et al. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. , 1998, Journal of andrology.
[91] B. Goodpaster,et al. The analog free testosterone assay: are the results in men clinically useful? , 1998, Clinical chemistry.
[92] J. Bilezikian,et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. , 1998, The New England journal of medicine.
[93] A. Iranmanesh,et al. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study. , 1998, The Journal of clinical endocrinology and metabolism.
[94] D. Jorkasky,et al. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. , 1998, Clinical therapeutics.
[95] S. Arver,et al. Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men , 1997, Clinical endocrinology.
[96] Zhiling Yu,et al. Transdermal Testosterone Administration in Hypogonadal Men: Comparison of Pharmacokinetics at Different Sites of Application and at the First and Fifth Days of Application , 1997, Journal of clinical pharmacology.
[97] Zhiling Yu,et al. Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men , 1997, Journal of clinical pharmacology.
[98] J. Morley,et al. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. , 1997, The Journal of clinical endocrinology and metabolism.
[99] I. Thompson,et al. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. , 1997, The Journal of urology.
[100] David Handelsman,et al. An analysis of testosterone implants for androgen replacement therapy , 1997, Clinical endocrinology.
[101] T. Link,et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. , 1997, The Journal of clinical endocrinology and metabolism.
[102] M. Zacharin,et al. Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets , 1997, Archives of disease in childhood.
[103] H. Perry,et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. , 1997, The Journal of clinical endocrinology and metabolism.
[104] M. Lundie,et al. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. , 1997, The Journal of urology.
[105] R. Casaburi,et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. , 1997, The Journal of clinical endocrinology and metabolism.
[106] W. DeWolf,et al. Occult prostate cancer in men with low serum testosterone levels. , 1996, JAMA.
[107] D. Schoenfeld,et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. , 1996, The Journal of clinical endocrinology and metabolism.
[108] R. Swerdloff,et al. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.
[109] K. Nair,et al. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.
[110] A. Iranmanesh,et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.
[111] F. Jockenhövel,et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men , 1996, Clinical endocrinology.
[112] M. Vallotton. Primary aldosteronism. Part II Differential diagnosis of primary hyperaldosteronism and pseudoaldosteronism , 1996, Clinical endocrinology.
[113] S. Arver,et al. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.
[114] S. Arver,et al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. , 1996, The Journal of urology.
[115] W. Bremner,et al. Androgens in men--uses and abuses. , 1996, The New England journal of medicine.
[116] S. Lim,et al. Site-specific effect of testosterone on bone mineral density in male hypogonadism. , 1995, Journal of Korean medical science.
[117] E. Simpson,et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. , 1995, The Journal of clinical endocrinology and metabolism.
[118] G. Alexander,et al. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study. , 1995, The Journal of clinical endocrinology and metabolism.
[119] David Handelsman,et al. Andrology: Tolerability of intramuscular injections of testosterone ester in oil vehicle , 1995 .
[120] O. Arisaka,et al. Effect of testosterone on bone density and bone metabolism in adolescent male hypogonadism. , 1995, Metabolism: clinical and experimental.
[121] K. Korach,et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. , 1994, The New England journal of medicine.
[122] B. de Lignières,et al. Transdermal dihydrotestosterone treatment of 'andropause'. , 1993 .
[123] H. Perry,et al. Effects of Testosterone Replacement Therapy in Old Hypogonadal Males: A Preliminary Study , 1993, Journal of the American Geriatrics Society.
[124] E. Nieschlag,et al. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. , 1992, The Journal of clinical endocrinology and metabolism.
[125] J. S. Tenover,et al. Effects of testosterone supplementation in the aging male. , 1992, The Journal of clinical endocrinology and metabolism.
[126] J. Devogelaer,et al. Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. , 1992, Maturitas.
[127] M. Riggs,et al. Testosterone Deficiency As a Risk Factor for Hip Fractures in Men: A Case‐Control Study , 1992, The American journal of the medical sciences.
[128] C. Bardin,et al. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. , 1992, Endocrinology.
[129] K. Tolman,et al. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. , 1992, The Journal of clinical endocrinology and metabolism.
[130] S. Yen,et al. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. , 1991, The Journal of clinical endocrinology and metabolism.
[131] S. Posen,et al. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[132] M. Rajalakshmi,et al. Pharmacokinetics and pharmacodynamics of a new long-acting androgen ester: maintenance of physiological androgen levels for 4 months after a single injection. , 1989, Contraception.
[133] W. Bremner,et al. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. , 1989, Journal of andrology.
[134] J. Findlay,et al. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. , 1989, The Journal of clinical endocrinology and metabolism.
[135] W. Crowley,et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. , 1988, The Journal of clinical endocrinology and metabolism.
[136] L. Ewing,et al. Initial trial of slow-release testosterone microspheres in hypogonadal men. , 1988, Fertility and sterility.
[137] David Handelsman,et al. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. , 1988, International journal of andrology.
[138] M. Vance,et al. Transdermal testosterone treatment of hypogonadal men. , 1988, The Journal of urology.
[139] K. Langer,et al. Substitution therapy of hypogonadal men with transdermal testosterone over one year. , 1988, Acta endocrinologica.
[140] R. Santen,et al. Transdermal testosterone therapy in the treatment of male hypogonadism. , 1988, The Journal of clinical endocrinology and metabolism.
[141] H. Nankin. Hormone kinetics after intramuscular testosterone cypionate. , 1987, Fertility and sterility.
[142] W. Crowley,et al. Osteoporosis in Men with Idiopathic Hypogonadotropic Hypogonadism , 1987 .
[143] A. Klibanski,et al. Osteoporosis in men with hyperprolactinemic hypogonadism. , 1986, Annals of internal medicine.
[144] M. Vitiello,et al. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. , 1983, The Journal of clinical endocrinology and metabolism.
[145] J. Fiet,et al. Percutaneous absorption of 5 alpha-dihydrotestosterone in man. II. Percutaneous administration of 5 alpha-dihydrotestosterone in hypogonadal men with idiopathic haemochromatosis; clinical, metabolic and hormonal effectiveness. , 1982, International journal of andrology.
[146] J. Fiet,et al. Percutaneous absorption of 5α-dihydrotestosterone in man.: I. Plasma androgen and gonadotrophin levels in normal adult men after percutaneous administration of 5α-dihydrotestosterone , 1982 .
[147] P. Snyder,et al. Treatment of male hypogonadism with testosterone enanthate. , 1980, The Journal of clinical endocrinology and metabolism.
[148] E. Nieschlag,et al. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate. , 1980, Fertility and sterility.
[149] A. Kenny,et al. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. , 2004, The journals of gerontology. Series A, Biological sciences and medical sciences.
[150] A. Morales,et al. Androgen deficiency in the aging male. , 2003, International journal of impotence research.
[151] A. Siegel,et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. , 2003, The American journal of psychiatry.
[152] T. Link,et al. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. , 1998, European journal of endocrinology.
[153] M. Tschöp,et al. A Time-Resolved Fluorescence Immunoassay for the Measurement of Testosterone in Saliva: Monitoring of Testosterone Replacement Therapy with Testosterone Buciclate , 1998, Clinical chemistry and laboratory medicine.
[154] W. Jordan,et al. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. , 1998, Clinical therapeutics.
[155] A. Dobs,et al. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. , 1998, The Journal of clinical endocrinology and metabolism.
[156] M. Pandian,et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. , 1992, The Journal of clinical endocrinology and metabolism.
[157] H. Croxatto,et al. Pharmacokinetics and metabolism of RU 486. , 1987, Journal of steroid biochemistry.